CO2019011018A2 - Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas - Google Patents

Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas

Info

Publication number
CO2019011018A2
CO2019011018A2 CONC2019/0011018A CO2019011018A CO2019011018A2 CO 2019011018 A2 CO2019011018 A2 CO 2019011018A2 CO 2019011018 A CO2019011018 A CO 2019011018A CO 2019011018 A2 CO2019011018 A2 CO 2019011018A2
Authority
CO
Colombia
Prior art keywords
potency
assay
receptor
nanomedicines
measure
Prior art date
Application number
CONC2019/0011018A
Other languages
English (en)
Inventor
Pedro Santamaria
Original Assignee
Uti Lp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uti Lp filed Critical Uti Lp
Publication of CO2019011018A2 publication Critical patent/CO2019011018A2/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)

Abstract

En este documento, se describe una célula aislada que comprende un receptor de células T recombinante (TCR) y un marcador dependiente de la vía TCR, en donde el receptor de células T recombinante es específico para un antígeno relevante para la enfermedad unido a una molécula de MHC. También se describen métodos de uso para una célula aislada, como un ensayo para determinar la función o la potencia de un complejo mayor de histocompatibilidad de un péptido (pMHC), acoplado a una nanopartícula (pMHC-NP), que se puede usar como medicamento para tratar una enfermedad autoinmune o cáncer.
CONC2019/0011018A 2017-04-07 2019-10-04 Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas CO2019011018A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762483298P 2017-04-07 2017-04-07
PCT/IB2018/000510 WO2018185564A2 (en) 2017-04-07 2018-04-05 Assay to measure the potency of receptor-ligand interactions in nanomedicines

Publications (1)

Publication Number Publication Date
CO2019011018A2 true CO2019011018A2 (es) 2019-10-21

Family

ID=63713282

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2019/0011018A CO2019011018A2 (es) 2017-04-07 2019-10-04 Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas

Country Status (14)

Country Link
US (1) US20200057048A1 (es)
EP (1) EP3607058A4 (es)
JP (1) JP2020516594A (es)
KR (1) KR20200004807A (es)
CN (1) CN110945120A (es)
AU (1) AU2018248961A1 (es)
BR (1) BR112019021022A2 (es)
CA (1) CA3059016A1 (es)
CO (1) CO2019011018A2 (es)
IL (1) IL269846A (es)
MX (1) MX2019012058A (es)
RU (1) RU2019135533A (es)
SG (1) SG11201909290TA (es)
WO (1) WO2018185564A2 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
MX2016005822A (es) 2013-11-04 2016-12-02 Uti Limited Partnership Metodos y composiciones para inmunoterpia sostenida.
CA3232037A1 (en) * 2021-09-21 2023-03-30 Monash University Methods of treatment
CN113960003B (zh) * 2021-10-20 2023-10-24 吉林大学 基于dna银纳米簇和金纳米棒检测四环素的适配体传感器
US11873507B2 (en) 2021-11-29 2024-01-16 Replicate Bioscience, Inc. Compositions and methods for expression of IL-12 and IL-1RA
EP4249062A1 (en) * 2022-03-24 2023-09-27 Julius-Maximilians-Universität Würzburg Mhc ib-mediated aquaporin 4 (aqp4)-specific immunosuppression as a novel treatment for nmo
CN115125205A (zh) * 2022-06-14 2022-09-30 中国医学科学院生物医学工程研究所 一种修饰EpCAM抗体和/或CSV抗体的白细胞磁球及其制备方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0417954D0 (en) * 2004-08-12 2004-09-15 Avidex Ltd Cellulat TCR ligand assay method
JP5650406B2 (ja) * 2007-03-07 2015-01-07 ユーティーアイ リミテッド パートナーシップ 自己免疫状態の予防および治療のための組成物および方法
US8809057B2 (en) * 2012-01-04 2014-08-19 Raytheon Bbn Technologies Corp. Methods of evaluating gene expression levels
DK3220927T3 (en) * 2014-11-20 2022-02-14 Promega Corp Systems and methods for assessing modulators of immune checkpoints
CN107995926B (zh) * 2014-12-19 2021-07-06 苏黎世联邦理工学院 嵌合抗原受体和使用方法
EP3067366A1 (en) * 2015-03-13 2016-09-14 Max-Delbrück-Centrum Für Molekulare Medizin Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1
CN115537396A (zh) * 2015-03-27 2022-12-30 哈佛学院校长同事会 经过修饰的t细胞及其制备和使用方法
CA2984485A1 (en) * 2015-05-06 2016-12-15 Uti Limited Partnership Nanoparticle compositions for sustained therapy
NZ737400A (en) * 2015-06-01 2019-09-27 Medigene Immunotherapies Gmbh T cell receptor library
MA44907A (fr) * 2015-09-11 2018-07-18 Agenus Inc Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation

Also Published As

Publication number Publication date
MX2019012058A (es) 2019-11-11
WO2018185564A2 (en) 2018-10-11
CA3059016A1 (en) 2018-10-11
BR112019021022A2 (pt) 2020-06-09
US20200057048A1 (en) 2020-02-20
RU2019135533A (ru) 2021-05-07
AU2018248961A1 (en) 2019-10-31
KR20200004807A (ko) 2020-01-14
JP2020516594A (ja) 2020-06-11
EP3607058A2 (en) 2020-02-12
EP3607058A4 (en) 2020-12-16
WO2018185564A3 (en) 2019-01-03
CN110945120A (zh) 2020-03-31
IL269846A (en) 2019-11-28
SG11201909290TA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
CO2019011018A2 (es) Ensayo para medir la potencia de las interaccioned del receptor-ligando en nanomedicinas
BR112019007100A2 (pt) composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão
CL2022003264A1 (es) Péptidos y sus combinaciones para uso en inmunoterapia contra el cáncer de próstata y otros
CY1122720T1 (el) Υποδοχεις τ κυτταρων που αναγνωριζουν περιορισμενη μαgε-α3 μηc ταξης ii
ECSP17027870A (es) Composiciones y métodos usados para aumentar la respuesta inmune y en la terapia del cáncer
CL2021002491A1 (es) Receptores de células t mage a4
CL2018002859A1 (es) Receptores de células t.
UY37278A (es) Anticuerpos anti-b7-h3 y conjugados de fármaco y anticuerpos
CL2018002763A1 (es) Moléculas de unión a bcma y métodos de uso de las mismas.
CL2020001181A1 (es) Nuevos receptores de células t modificados genéticamente y terapias inmunológicas que emplean los mismos.
EA202092032A1 (ru) Т-клеточный рецептор, специфичный в отношении ny-eso-1/lage-1, и его применения
BR112016027805A2 (pt) receptores de células t do anti-papilomavírus humano 16 e7
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
EA201992536A1 (ru) Tcr и пептиды
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
CL2018001427A1 (es) Composiciones de anticuerpo injertado con citoquina y métodos para su uso en inmunorregulación.
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
CL2019002093A1 (es) Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cáncer.
PE20151871A1 (es) Anticuerpos de receptor anti-glucagon y metodos de uso de los mismos
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
CL2019002880A1 (es) Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer.
BR112021025548A2 (pt) Receptores de células t mage-a4 e métodos de uso dos mesmos
CL2019002948A1 (es) Nuevos péptidos y combinación para el uso en la inmunoterapia contra varios tipo de cáncer. (divisional solicitud 201801533)
BR112019011461A2 (pt) terapia celular à base de nk melhorada
EA201990543A1 (ru) Композиции и способы репрограммирования т-клеточных рецепторов с помощью гибридных белков